You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.
MANATEE: GYM329 (RO7204239) in Combination with Risdiplam▼ Treatment in Ambulant Children with Spinal Muscular Atrophy
MANATEE (NCT05115110) is a multicenter, two-part, randomized, placebo-controlled, double-blind study that will investigate the effect of GYM329 in combination with risdiplam▼ in treatment-naïve and non-treatment-naïve ambulant patients, aged 2–10 years at screening. Part 1 will assess safety, tolerability and pharmacokinetics/pharmacodynamics of different GYM329 doses in combination with risdiplam▼. Part 2 will assess efficacy and safety of the Part 1-selected dose of GYM329 in combination with risdiplam▼. This poster presentation will provide information about safety and efficacy of GYM329 in combination with risdiplam▼ treatment in ambulant pediatric patients with SMA.
Request medical material
Would you like to receive this poster via email to view later?